PhaseBio Raises $40 Million Series C Financing Led by

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PhaseBio Raises $40 Million Series C Financing Led by AstraZeneca
  • Proceeds to enable advancement of lead drug candidates – once-weekly basal insulin and once-weekly Vasoactive Intestinal Peptide

MALVERN, Pa., March 12, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a leading company in the field of biopolymer-based drugs and focused on developing treatments for metabolic and specialty cardiopulmonary disorders, today announced that it has closed a $40 million Series C financing round led by AstraZeneca. Investment by AstraZeneca and existing investors New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Innovation – JJDC and Fletcher Spaght Ventures will enable progression of PhaseBio's once-weekly insulin (PE0139) into Phase 2a testing for type 2 diabetes and once-weekly Vasoactive Intestinal Peptide (PB1046) into separate Phase 2a trials for heart failure and for cardiomyopathy in Duchenne and Becker muscular dystrophy. Michael Gutch, Ph.D., M.B.A., Executive Director of Corporate Development at AstraZeneca, has joined PhaseBio's board of directors. Donald Dwyer, M.B.A., Executive Director of Evaluations at AstraZeneca has joined as a board observer of PhaseBio.

PE0139 is a first-in-class, super long-acting, fully native basal insulin intended for once-weekly subcutaneous administration, either as a monotherapy or in combination with other treatments for type 2 diabetes. PB1046 is comprised of a recombinant form of the human peptide hormone Vasoactive Intestinal Peptide (VIP) that stimulates biological pathways important in the regulation of the cardiopulmonary and immune systems. Both compounds utilize PhaseBio's proprietary Elastin-Like Polypeptide (ELP) technology to provide longer half-life and greater stability in circulation while retaining similar potency to the native sequences.

"AstraZeneca is committed to bringing innovative treatments to improve the life of diabetic patients," said Dr. Gutch. "The ELP technology developed by PhaseBio might offer to patients the opportunity to manage their diabetes by injecting once-weekly, long-acting basal insulin."  

"The investment from AstraZeneca, together with our existing investors, provides PhaseBio with a great deal of operational flexibility and resources to advance PE0139 into a Phase 2a study, as well as to initiate Phase 2a trials of PB1046 for acute heart failure and for cardiomyopathy in Duchenne and Becker muscular dystrophy patients," said Jonathan P. Mow, Chief Executive Officer of PhaseBio. "Given the broad potential for PB1046 to treat both heart failure and orphan diseases, we have the flexibility to either develop and launch the product on our own or in collaboration with a partner."

About PE0139

PE0139 is the result of PhaseBio's internal research efforts, which enabled native human insulin to be produced in E. coli as a correctly folded soluble protein when fused to an Elastin-Like Polypeptide (ELP). The product is formulated in an aqueous solution at a neutral pH and has been shown to be highly potent in vivo, with a more prolonged effect on blood glucose than insulin glargine. PE0139 is differentiated from currently available basal insulins as the only agent to be based on the native insulin sequence, rather than a mutated sequence, and by its ability to remain stable in monomeric form in a simple aqueous formulation. PE0139 has an extremely flat pharmacokinetic profile that is essential for the once-weekly delivery of insulin.

About PB1046

PB1046 is based on Vasoactive Intestinal Peptide (VIP), a naturally occurring peptide with multiple pleiotropic effects on the cardiovascular, pulmonary and immune systems. However, the extremely short in vivo half-life has precluded its therapeutic use. Utilizing ELP technology, PhaseBio has overcome these limitations, demonstrating prolonged circulatory drug exposure in humans. PB1046 was highly effective in animal models of hypertension, pulmonary arterial hypertension and heart failure, with positive cardiac inotropic (contractility) and lusitropic (relaxation) effects without an increase in myocardial oxygen demand.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company's proprietary discovery platform technology uses recombinant ELP biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are tuned for a specific rate of absorption, thereby increasing efficacy and reducing side effects. The Company's lead development candidates are PE0139, a novel basal insulin ELP-fusion with the potential for weekly dosing; and PB1046, a weekly VIP agonist for treatment of acute and chronic heart failure and Duchenne muscular dystrophy-associated cardiomyopathy. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA.

Media Contact: Laura Bagby, 6 Degrees (312) 448-8098

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 84

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 69

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Sivers Moves Q3 Release to Accommodate U.S. Investors

Updated Category News Views 74

Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading

Top 5 Most Recently Viewed Articles

American Teachers Alliance Initiates Empowering Programs for Students

Updated Category News Views 143

Empowering Future Educators with College Chapters In a progressive move to inspire and support the upcoming generation of teachers, the American Teachers Alliance (ATA) has launched a significant initiative aimed at engaging college students across universities. This initiative introduces college student chapters, fostering a community where aspiring educators can enhance...

Continue Reading
Enhancing Enterprise Collaboration: Progress ShareFile and Microsoft 365

Updated Category News Views 190

Introduction to Progress ShareFile's New Features Progress, a leading provider of AI-driven digital experience and infrastructure software, is excited to announce significant advancements to its ShareFile platform. The recent updates mark a transformative leap in how enterprises collaborate using Microsoft 365, empowering teams to work more securely and efficiently. Deep...

Continue Reading
Shareholder Alert: Investigations on Major Mergers for 2025

Updated Category News Views 314

Investigating Significant Mergers in 2025 In the financial landscape, the merging of companies can significantly impact shareholders. Recognizing the importance of every shareholder's voice, we delve into several notable mergers that are under scrutiny as we approach votes critical to shareholders. As many companies opt for merger routes, understanding the implications of...

Continue Reading
Explore the Vibrant Daylight Shows Series in NYC's Hotspots

Updated Category News Views 181

Unveiling the Daylight Shows at Daylight Studio Experience the vibrant world of creativity at Daylight Studio, a prominent event venue nestled in two of New York City's most dynamic areas, Hudson Yards and Flatiron. With years of experience in supporting film, fashion, and artistic endeavors, Daylight Studio has secured its place as a go-to location for creatives and...

Continue Reading
Ventyx Biosciences Begins Phase 2a Trial for Parkinson’s Treatment

Updated Category News Views 138

Ventyx Biosciences Begins Phase 2a Trial for VTX3232 Ventyx Biosciences, Inc. (Nasdaq: VTYX), a company focused on creating innovative oral treatments for various inflammatory diseases, has announced the start of dosing for its Phase 2a clinical trial of VTX3232. This important trial is centered on individuals who have been diagnosed with the early stages of Parkinson’s...

Continue Reading